Baillie Gifford acquired 10.2 Million Sana Biotechnology shares worth $18.4 Million. That's 0.02% of their equity portfolio (178th largest holding). The investor owns 4.33% of the outstanding Sana Biotechnology stock. The first Sana Biotechnology trade was made in Q1 2021. Since then Baillie Gifford bought shares four more times and sold shares on twelve occasions. The investor's estimated purchase price is $307 Million, resulting in a loss of 94%.